United Therapeutics Depreciation And Amortization Over Time
| UTHR Stock | USD 359.58 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out United Therapeutics Performance and United Therapeutics Correlation. United |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.188 | Earnings Share 22.77 | Revenue Per Share 60.245 | Quarterly Revenue Growth 0.229 | Return On Assets 0.1189 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Depreciation And Amortization Analysis
Compare United Therapeutics and related stocks such as Incyte, Alnylam Pharmaceuticals, and Ultragenyx Depreciation And Amortization Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCY | 400 K | 27 M | 30 M | 29.2 M | 41.4 M | 44.9 M | 58.4 M | 52.2 M | 55 M | 71.9 M | 51.8 M | 57.8 M | 67.9 M | 82.7 M | 86.8 M |
| ALNY | 36 K | 5.1 M | 9 M | 10.2 M | 11.9 M | 19.1 M | 15.1 M | 13.4 M | 161.1 K | 54.4 M | 34.8 M | 47.6 M | 44.5 M | 54.1 M | 56.8 M |
| RARE | 34 K | 34 K | 313 K | 444 K | 684 K | 1.4 M | 3.4 M | 5.8 M | 19.5 M | 12.5 M | 12.3 M | 13.2 M | 18.2 M | 26 M | 27.3 M |
| APLS | 6.3 K | 6.3 K | 6.3 K | 6.3 K | 6.6 K | 53 M | 11.9 K | 11.9 K | 2.9 M | 5.2 M | 859 K | 1.5 M | 1.5 M | 1.7 M | 1.6 M |
| REPL | 122 K | 122 K | 122 K | 122 K | 122 K | 122 K | 122 K | 109 K | 148 K | 533 K | 4.1 M | 4.6 M | 2.4 M | 2.7 M | 2 M |
| NUVL | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | 2.3 M | (306 K) | 8.5 M | 167.9 K | 159.5 K |
| VTYX | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | 7 M | 30 K | 470 K | 158 K | 150.1 K |
| ASND | 425 K | 425 K | 425 K | 405 K | 504 K | 558 K | 677 K | 734 K | 880 K | 9.7 M | 8.8 M | 16 M | 17.6 M | 18.9 M | 19.9 M |
| MNKD | (204 K) | 15.9 M | 14.4 M | 14.1 M | 18.6 M | 13.3 M | 4.2 M | 3.5 M | 2.9 M | 71 K | 3 M | 3.3 M | 6.3 M | 4.5 M | 8.2 M |
| LRMR | 70 K | 70 K | 70 K | 70 K | 70 K | 70 K | 212 K | 188 K | 261 K | 78 K | 155 K | 326 K | 318 K | 311 K | 234.5 K |
| DAWN | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | (2 K) | 155 K | 199 K | 531 K | 383 K | 278.5 K |
| KNSA | 22 K | 22 K | 22 K | 22 K | 22 K | 22 K | 22 K | 28 K | 286 K | 2.1 M | 2.4 M | 2.4 M | 4.2 M | 2.3 M | 1.9 M |
| BGNE | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.5 M | 1.9 M | 4.8 M | 10.4 M | 1.3 M | 31.8 M | 46.5 M | 66.3 M | 87.7 M | 92.1 M |
| AKRO | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | 17 K | 17 K | 41 K | 260 K | 29 K | 30.4 K |
| BPMC | 501 K | 501 K | 501 K | 501 K | 622 K | 948 K | 1.6 M | 1.6 M | 4.2 M | 10.2 M | 12.3 M | 12.8 M | 20.1 M | 11.7 M | 7.7 M |
| PCVX | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 5.3 M | 1.4 M | 1.8 M | 9.2 M | 3.2 M | 4 M |
| LEGN | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 1.7 M | 5.3 M | 9.9 M | 13.9 M | 18.4 M | 20.5 M | 11 M |
United Therapeutics and related stocks such as Incyte, Alnylam Pharmaceuticals, and Ultragenyx Depreciation And Amortization description
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.My Equities
My Current Equities and Potential Positions
| United Therapeutics | UTHR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Maryland; U.S.A |
| Exchange | NASDAQ Exchange |
USD 359.58
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.